Terms: = Lung cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Clinical Outcome
61 results:
1. Prognostic impact of age in advanced non-small cell lung cancer patients undergoing first-line checkpoint inhibitor immunotherapy and chemotherapy treatment.
Huang X; Wu S; Chen S; Qiu M; Zhao Y; Wei J; He J; Zhao W; Tan L; Su C; Zhou S
Int Immunopharmacol; 2024 May; 132():111901. PubMed ID: 38554448
[TBL] [Abstract] [Full Text] [Related]
2. A review on the role of HAND2-AS1 in cancer.
Ghafouri-Fard S; Hussen BM; Abdullah SR; Dadyar M; Taheri M; Kiani A
Clin Exp Med; 2023 Nov; 23(7):3179-3188. PubMed ID: 37204522
[TBL] [Abstract] [Full Text] [Related]
3. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Negrao MV; Araujo HA; Lamberti G; Cooper AJ; Akhave NS; Zhou T; Delasos L; Hicks JK; Aldea M; Minuti G; Hines J; Aredo JV; Dennis MJ; Chakrabarti T; Scott SC; Bironzo P; Scheffler M; Christopoulos P; Stenzinger A; Riess JW; Kim SY; Goldberg SB; Li M; Wang Q; Qing Y; Ni Y; Do MT; Lee R; Ricciuti B; Alessi JV; Wang J; Resuli B; Landi L; Tseng SC; Nishino M; Digumarthy SR; Rinsurongkawong W; Rinsurongkawong V; Vaporciyan AA; Blumenschein GR; Zhang J; Owen DH; Blakely CM; Mountzios G; Shu CA; Bestvina CM; Garassino MC; Marrone KA; Gray JE; Patel SP; Cummings AL; Wakelee HA; Wolf J; Scagliotti GV; Cappuzzo F; Barlesi F; Patil PD; Drusbosky L; Gibbons DL; Meric-Bernstam F; Lee JJ; Heymach JV; Hong DS; Heist RS; Awad MM; Skoulidis F
Cancer Discov; 2023 Jul; 13(7):1556-1571. PubMed ID: 37068173
[TBL] [Abstract] [Full Text] [Related]
4. Positive
Huang S; Qi M; Tian T; Dai H; Tang Y; Huang R
Front Endocrinol (Lausanne); 2022; 13():959089. PubMed ID: 36407316
[TBL] [Abstract] [Full Text] [Related]
5. Genetic variants in LKB1/AMPK/mTOR pathway are associated with clinical outcomes of chemotherapy in non-small cell lung cancer.
Choi SH; Do SK; Lee SY; Choi JE; Kang HG; Hong MJ; Lee JH; Lee WK; Jeong JY; Shin KM; Do YW; Lee EB; Park JE; Lee YH; Seo H; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
Thorac Cancer; 2022 Dec; 13(23):3322-3330. PubMed ID: 36239337
[TBL] [Abstract] [Full Text] [Related]
6. Relationship between the microRNAs and PI3K/akt/mTOR axis: Focus on non-small cell lung cancer.
Lin Y; Zhang L; Ding X; Chen C; Meng M; Ke Y; Wang W
Pathol Res Pract; 2022 Nov; 239():154093. PubMed ID: 36183437
[TBL] [Abstract] [Full Text] [Related]
7. TRIM46 activates akt/HK2 signaling by modifying PHLPP2 ubiquitylation to promote glycolysis and chemoresistance of lung cancer cells.
Tantai J; Pan X; Chen Y; Shen Y; Ji C
Cell Death Dis; 2022 Mar; 13(3):285. PubMed ID: 35354796
[TBL] [Abstract] [Full Text] [Related]
8. Mutations and clinical significance of calcium voltage-gated channel subunit alpha 1E (CACNA1E) in non-small cell lung cancer.
Gao SH; Wang GZ; Wang LP; Feng L; Zhou YC; Yu XJ; Liang F; Yang FY; Wang Z; Sun BB; Wang D; Liang LJ; Xie DW; Zhao S; Feng HP; Li X; Li KK; Tang TS; Huang YC; Wang SQ; Zhou GB
Cell Calcium; 2022 Mar; 102():102527. PubMed ID: 35026540
[TBL] [Abstract] [Full Text] [Related]
9. Identification and functional analysis of lncRNAs and mRNAs between tumorigenesis and metastasis in CRC.
Liu H; Tian Y; Li J; Zhang G; Liu Q; Yang M; Yue L; Cao Q; Zhang G; Cheng Y; Kong N; Fang L; Li S; Sun Q
Aging (Albany NY); 2021 Dec; 13(24):25859-25885. PubMed ID: 34954693
[TBL] [Abstract] [Full Text] [Related]
10. Silencing FYVE, RhoGEF, and PH domain containing 1 (FGD1) suppresses melanoma progression by inhibiting PI3K/akt signaling pathway.
Niu Z; Li Y; Xu Y; Jiang W; Tao R; Chen Y; Han Y
Bioengineered; 2021 Dec; 12(2):12193-12205. PubMed ID: 34783295
[TBL] [Abstract] [Full Text] [Related]
11. ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer.
Reissig TM; Sara L; Ting S; Reis H; Metzenmacher M; Eberhardt WEE; Zaun G; Herold T; Aigner C; Darwiche K; Stuschke M; Schildhaus HU; Schuler M; Wiesweg M
Lung Cancer; 2020 Nov; 149():10-16. PubMed ID: 32947221
[TBL] [Abstract] [Full Text] [Related]
12. Elevated SRC3 expression predicts pemetrexed resistance in lung adenocarcinoma.
Chen Y; Sun Y; Zhao W; Ma Y; Yan Z; Nie X
Biomed Pharmacother; 2020 May; 125():109958. PubMed ID: 32036219
[TBL] [Abstract] [Full Text] [Related]
13. Keratin 17 activates akt signalling and induces epithelial-mesenchymal transition in oesophageal squamous cell carcinoma.
Liu Z; Yu S; Ye S; Shen Z; Gao L; Han Z; Zhang P; Luo F; Chen S; Kang M
J Proteomics; 2020 Jan; 211():103557. PubMed ID: 31669361
[TBL] [Abstract] [Full Text] [Related]
14. Elevated TRIP13 drives the akt/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.
Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB
J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816
[TBL] [Abstract] [Full Text] [Related]
15. Role of miRNA-Regulated cancer Stem Cells in the Pathogenesis of Human Malignancies.
Khan AQ; Ahmed EI; Elareer NR; Junejo K; Steinhoff M; Uddin S
Cells; 2019 Aug; 8(8):. PubMed ID: 31530793
[TBL] [Abstract] [Full Text] [Related]
16. Resveratrol inhibits the invasion and metastasis of colon cancer through reversal of epithelial‑ mesenchymal transition via the akt/GSK‑3β/Snail signaling pathway.
Yuan L; Zhou M; Huang D; Wasan HS; Zhang K; Sun L; Huang H; Ma S; Shen M; Ruan S
Mol Med Rep; 2019 Sep; 20(3):2783-2795. PubMed ID: 31524255
[TBL] [Abstract] [Full Text] [Related]
17. Correlation between immunohistochemistry and RICTOR fluorescence in situ hybridization amplification in small cell lung carcinoma.
Krencz I; Sebestyen A; Papay J; Lou Y; Lutz GF; Majewicz TL; Khoor A
Hum Pathol; 2019 Nov; 93():74-80. PubMed ID: 31454632
[TBL] [Abstract] [Full Text] [Related]
18. Impact of single nucleotide polymorphisms on the efficacy and toxicity of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients.
Pérez-Ramírez C; Cañadas-Garre M; Molina MÁ; Cabeza Barrera J; Faus-Dáder MJ
Mutat Res Rev Mutat Res; 2019; 781():63-70. PubMed ID: 31416579
[TBL] [Abstract] [Full Text] [Related]
19. akt-mediated phosphorylation enhances protein stability and transcription activity of ZNF322A to promote lung cancer progression.
Liao SY; Kuo IY; Chen YT; Liao PC; Liu YF; Wu HY; Lai WW; Wang YC
Oncogene; 2019 Oct; 38(41):6723-6736. PubMed ID: 31399647
[TBL] [Abstract] [Full Text] [Related]
20. Carcinogen-induced tumors in SFN-transgenic mice harbor a characteristic mutation spectrum of human lung adenocarcinoma.
Kim Y; Shiba-Ishii A; Ramirez K; Muratani M; Sakamoto N; Iijima T; Noguchi M
Cancer Sci; 2019 Aug; 110(8):2431-2441. PubMed ID: 31144406
[TBL] [Abstract] [Full Text] [Related]
[Next]
